|
NGX-4010 for the Treatment of Postherpetic Neuralgia Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on NGX-4010 for the Treatment of Postherpetic Neuralgia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. NGX-4010 for the Treatment of Postherpetic Neuralgia Clinical research trials and NGX-4010 for the Treatment of Postherpetic Neuralgia healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including NGX-4010 for the Treatment of Postherpetic Neuralgia. NGX-4010 for the Treatment of Postherpetic Neuralgia Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a NGX-4010 for the Treatment of Postherpetic Neuralgia clinical trial. Test subjects oftentimes recieve the best healthcare possible for their NGX-4010 for the Treatment of Postherpetic Neuralgia condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > NGX-4010 for the Treatment of Postherpetic Neuralgia  NGX-4010 for the Treatment of Postherpetic Neuralgia
NGX-4010 for the Treatment of Postherpetic Neuralgia
For Condition: Shingles,Peripheral Nervous System Diseases,Pain,Herpes Zoster,Neuralgia
Status: No longer recruiting
Sponsor(s): NeurogesX ,
Synopsis: The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).
Details: Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin). Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Dose Comparison, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Key Eligibility Criteria: • Must be diagnosed with PHN and be at least 6 months after crusting of the skin vesicles, with moderate to severe pain. • Must not have significant pain due to causes other than PHN (for example, arthritis). • Painful areas should not be located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes. • Must have intact and unbroken skin at the treatment area. • Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (1-year). • Must not have any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of pain. • Must not use topical pain medications for PHN. • Must be able to comply with study requirements such as completing a daily pain diary, attending study visits and refraining from extensive travel during study participation. • No significant medical problems of the heart, kidneys, liver or lungs, or cancer. • No history or current problem with substance abuse.
Total Enrollment: 300
Location and Contact Information:
Comprehensive Neuroscience, Inc.
St. Petersburg, Florida, 33702
United States
Radiant Research
Austin, Texas, 78758
United States
Colorado Neurology & Headache Center
Denver, Colorado, 80218
United States
Lifetree Clinical Research
Salt Lake City, Utah, 84107
United States
Comprehensive Neuroscience, Inc.
Melbourne, Florida, 32935
United States
Renstar Medical Research
Ocala, Florida, 34471
United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115
United States
Methodist Comprehensive Pain Inst.
Memphis, Tennessee, 93104
United States
Upstate Clinical Research
Albany, New York, 12205
United States
Radiant Research
Scottsdale, Arizona,
United States
The Pain Institute, Research Medical Center
Kansas City, Missouri, 64132
United States
University of Rochester
Rochester, New York, 14642
United States
Clinical Study Center
Little Rock, Arkansas, 72205
United States
First Clinical Research
San Francisco, California, 94117
United States
Palm Beach Neurological Center
Palm Beach Gardens, Florida, 33410
United States
Internal Medicine Northwest
Tacoma, Washington, 98405
United States
Neuroscience Center of Northern New Jersey
Morristown, New Jersey, 07960
United States
Comprehensive Neuroscience, Inc.
Sarasota, Florida, 34232
United States
UCSD Pain Management Group
La Jolla, California, 92037
United States
Neurology Clinic of San Antonio
San Antonio, Texas, 78229
United States
Neurology Clinical Research, Inc.
Plantation, Florida, 33324
United States
Anchor Research Center
Naples, Florida, 34102
United States
Pain Consultants of Oregon
Eugene, Oregon, 97401
United States
University of Nevada
Las Vegas, Nevada, 89102
United States
Center for Pain Management and Rehabilitation
Huntsville, Alabama, 35801
United States
Arizona Research Center
Phoenix, Arizona, 85023
United States
University of Arizona
Tucson, Arizona, 85724
United States
Research Across America
Dallas, Texas, 75234
United States
Additional Information:
Study ID Numbers: C108;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061776
Other Pain Studies:
1. NGX-4010 for the Treatment of Postherpetic Neuralgia
2. Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
3. Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
4. Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
5. Neotrofin for treatment of chemotherapy-induced peripheral neuropathy
Related Studies:
Other Pain Clinical Trials
Other Colorado Clinical Trials
Other Denver Clinical Trials
NGX-4010 for the Treatment of Postherpetic Neuralgia
|
|
|
|
|
|
|
|
